Find your next paid study

~$75 – $2,800

Actual pay is set by the research site.

AbelZeta Inc.NCT07875413

A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

The overarching goals of this study are to measure levels of circulating tumor DNA (ctDNA) in patients with early stage diffuse large B cell lymphoma (DLBCL), …

DLBCL

University of RochesterNCT03758989

Actual pay is set by the research site.

Phase 1

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects With Advanced Solid Tumors (CHAMP-1)

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of R…

Advanced Solid TumorDLBCL

Ranok Therapeutics (Hangzhou) Co., Ltd.NCT05487170

~$150 – $4,200

Actual pay is set by the research site.

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell TherapyMultiple MyelomaDLBCL+2 more

Long-term Follow-up of Patients Previously Treated With Autologous T Cells Genetically Modified With Viral Vectors

Long-term follow-up of patients exposed to an AUTO CAR T cell therapy for up to 15 years following their first AUTO CAR T cell therapy infusion.

Autolus LimitedNCT03628612

~$75 – $2,800

Actual pay is set by the research site.

Diffuse Large B Cell Lymphoma (DLBCL)

Multicenter Phase II Study of Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

This single-arm, interventional phase 2 study is designed to evaluate whether the inclusion of mosunetuzumab subcutaneous and polatuzumab vedotin (Mosun-Pola) …

Medical College of WisconsinNCT06594939

Actual pay is set by the research site.

Phase 1

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients wit…

Ovarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more

~$150 – $4,200

Actual pay is set by the research site.

Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+6 more

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) i…

~$75 – $2,800

Actual pay is set by the research site.

Non-Hodgkin's B-cell LymphomaLymphoma Non-HodgkinDiffuse Large B-Cell Lymphoma (DLBCL)

Epcoritamab in Combination With R-CHOP Debulking in Newly Diagnosed Patients With Aggressive Non-Hodgkin Lymphoma (DLBCL)

A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggress…

Lymphoma, B-CellLymphomaLarge-cell Lymphoma+3 more

~$75 – $3,000

Actual pay is set by the research site.

Carrie Ho, MDNCT07588698

Observational

Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients a…

Memorial Sloan Kettering Cancer CenterNCT05940272

~$10 – $750

Actual pay is set by the research site.

Large B-cell LymphomaRelapseDLBCL+1 more

Phase 2 Study of Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

The purpose of this study is to determine whether combining Loncastuximab Tesirine with Epcoritamab is tolerable and effective for reducing and/or eliminating …

University of MiamiNCT06919939

Actual pay is set by the research site.

Diffuse Large B-cell Lymphoma (DLBCL)CardiotoxicityLymphoma

A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial

This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse…

Beth Israel Deaconess Medical CenterNCT07654426

Actual pay is set by the research site.

B-cell Non-Hodgkin LymphomaFollicular Lymphoma (FL)Large B-Cell Lymphoma (LBCL)

A Modular Phase 2, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants With Relapsed or Refractory (R/R) B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B)

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of surovatamig (AZD0486) monotherapy in adult particip…